{"id":"NCT02593097","sponsor":"Mayo Clinic","briefTitle":"Metformin for the Prevention of Episodic Migraine (MPEM)","officialTitle":"Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02","primaryCompletion":"2019-06","completion":"2019-06","firstPosted":"2015-10-30","resultsPosted":"2020-07-01","lastUpdate":"2020-07-01"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":["Placebo"]}],"arms":[{"label":"Metformin first, then matching placebo","type":"EXPERIMENTAL"},{"label":"Matching placebo first, then Metformin","type":"EXPERIMENTAL"}],"summary":"The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.","primaryOutcome":{"measure":"Headache Days","timeFrame":"Baseline through end of study for a total of approximately 32 weeks","effectByArm":[{"arm":"Metformin","deltaMin":23.64,"sd":2.15},{"arm":"Matching Placebo","deltaMin":24.33,"sd":2.19}],"pValues":[{"comp":"OG000 vs OG001","p":"0.83"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23831352"],"seeAlso":["https://www.mayo.edu/research/clinical-trials"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Dry Mouth","Diarrhea","Dry hair","Hair loss"]}}